Paraxanthine

Paraxanthine
Identifiers
CAS number 611-59-6 N
PubChem 4687
ChemSpider 4525 Y
UNII Q3565Y41V7 Y
ChEBI CHEBI:25858 Y
ChEMBL CHEMBL1158 Y
Jmol-3D images Image 1
Properties
Molecular formula C7H8N4O2
Molar mass 180.16 g/mol
Melting point

351-352 °C

 N (verify) (what is: Y/N?)
Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa)
Infobox references

Paraxanthine, or 1,7-dimethylxanthine, is a dimethyl derivative of xanthine, structurally related to caffeine. Like caffeine, paraxanthine is a psychoactive central nervous system (CNS) stimulant. It possesses a potency roughly equal to that of caffeine and is likely involved in the mediation of the effects of caffeine itself.

Contents

Production and metabolism

Paraxanthine is not produced by plants and is only observed in nature as a metabolite of caffeine in animals. After intake, roughly 84% of caffeine is demethylated at the 3-position to yield paraxanthine, making it the chief metabolite of caffeine in the body.[1]

Certain proposed synthetic pathways of caffeine make use of paraxanthine as a bypass intermediate. However, its absence in plant alkaloid assays implies that these are infrequently, if ever, directly produced by plants.

Physiological effects

Paraxanthine has a number of physiological effects on animals:

Toxicity

Paraxanthine is believed to exhibit a lower toxicity than caffeine.[7] While blood levels commensurate with average intake appear to be fairly innocuous, high blood concentrations of paraxanthine have been linked to miscarriage in pregnant mothers.[8]

References

  1. ^ Guerreiro S, Toulorge D, Hirsch E, Marien M, Sokoloff P, Michel PP (October 2008). "Paraxanthine, the primary metabolite of caffeine, provides protection against dopaminergic cell death via stimulation of ryanodine receptor channels". Mol. Pharmacol. 74 (4): 980–9. doi:10.1124/mol.108.048207. PMID 18621927. http://molpharm.aspetjournals.org/cgi/pmidlookup?view=long&pmid=18621927. 
  2. ^ Essayan DM. (2001). "Cyclic nucleotide phosphodiesterases.". J Allergy Clin Immunol. 108 (5): 671–80. doi:10.1067/mai.2001.119555. PMID 11692087. 
  3. ^ Deree J, Martins JO, Melbostad H, Loomis WH, Coimbra R. (2008). "Insights into the Regulation of TNF-α Production in Human Mononuclear Cells: The Effects of Non-Specific Phosphodiesterase Inhibition". Clinics (Sao Paulo). 63 (3): 321–8. doi:10.1590/S1807-59322008000300006. PMC 2664230. PMID 18568240. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2664230. 
  4. ^ Marques LJ, Zheng L, Poulakis N, Guzman J, Costabel U (February 1999). "Pentoxifylline inhibits TNF-alpha production from human alveolar macrophages". Am. J. Respir. Crit. Care Med. 159 (2): 508–11. PMID 9927365. http://ajrccm.atsjournals.org/cgi/pmidlookup?view=long&pmid=9927365. 
  5. ^ a b Peters-Golden M, Canetti C, Mancuso P, Coffey MJ. (2005). "Leukotrienes: underappreciated mediators of innate immune responses". J Immunol. 174 (2): 589–94. PMID 15634873. http://www.jimmunol.org/cgi/content/full/174/2/589. 
  6. ^ Daly JW, Jacobson KA, Ukena D. (1987). "Adenosine receptors: development of selective agonists and antagonists". Prog Clin Biol Res. 230 (1): 41–63. PMID 3588607. 
  7. ^ Neal L. Benowitz, Peyton Jacob, Haim Mayan and Charles Denaro (1995). "Sympathomimetic effects of paraxanthine and caffeine in humans". Clinical Pharmacology & Therapeutics 58 (58): 684–691. doi:10.1016/0009-9236(95)90025-X. http://www.nature.com/clpt/journal/v58/n6/abs/clpt1995184a.html. 
  8. ^ Mark A. Klebanoff, M.D., M.P.H., Richard J. Levine, M.D., M.P.H., Rebecca DerSimonian, Sc.D., John D. Clemens, M.D., and Diana G. Wilkins, Ph.D. (1999). "Maternal Serum Paraxanthine, a Caffeine Metabolite, and the Risk of Spontaneous Abortion". New England Journal of Medicine 341 (22): 1639–1644. doi:10.1056/NEJM199911253412202. PMID 10572151. http://content.nejm.org/cgi/content/full/341/22/1639.